Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSK-V101K (Omicron LP.8.1) booster versus NUVAXOVID in previously vaccinated adults
jRCT2031250539Phase 3Not yet recruiting
- Sponsor
- WestVac Biopharma
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of WSK-V101K in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by WestVac Biopharma. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
WSK-V101K
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031250539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250539.